Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F11%3A00002462" target="_blank" >RIV/00216208:11120/11:00002462 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/11:6941 RIV/00064173:_____/11:#0000168 RIV/00064203:_____/11:6941

Výsledek na webu

<a href="http://dx.doi.org/10.1111/j.1600-0463.2010.02685.x" target="_blank" >http://dx.doi.org/10.1111/j.1600-0463.2010.02685.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1600-0463.2010.02685.x" target="_blank" >10.1111/j.1600-0463.2010.02685.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients

Popis výsledku v původním jazyce

Epstein-Barr virus (EBV) is associated with approximately one-third of Hodgkin lymphoma (HL) cases. EBV-DNA is often present in the plasma and whole blood of EBV-associated HL patients. However, the significance of EBV-DNA monitoring is debated. In a cohort of 165 adult HL patients, EBV-DNA viral load was prospectively monitored both in the plasma and whole blood. Diagnostic tissue samples of all patients were histologically reviewed; in 72% nodular sclerosis was detected, 24% presented with mixed cellularity (MC), and 5% had other type of HL. Tissues from 150 patients were also analyzed for the presence of latent EBV infection using in situ hybridization for EBV-encoded RNA (EBER) and immunohistochemistry for latent membrane protein (LMP1). Using these methods, 29 (19%) patients were classified as EBV positive. Using real-time quantitative PCR, 22 (76%) of EBV-positive HL patients had detectable EBV-DNA in the plasma and 19 (66%) patients in whole blood prior to therapy. In the group

Název v anglickém jazyce

Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients

Popis výsledku anglicky

Epstein-Barr virus (EBV) is associated with approximately one-third of Hodgkin lymphoma (HL) cases. EBV-DNA is often present in the plasma and whole blood of EBV-associated HL patients. However, the significance of EBV-DNA monitoring is debated. In a cohort of 165 adult HL patients, EBV-DNA viral load was prospectively monitored both in the plasma and whole blood. Diagnostic tissue samples of all patients were histologically reviewed; in 72% nodular sclerosis was detected, 24% presented with mixed cellularity (MC), and 5% had other type of HL. Tissues from 150 patients were also analyzed for the presence of latent EBV infection using in situ hybridization for EBV-encoded RNA (EBER) and immunohistochemistry for latent membrane protein (LMP1). Using these methods, 29 (19%) patients were classified as EBV positive. Using real-time quantitative PCR, 22 (76%) of EBV-positive HL patients had detectable EBV-DNA in the plasma and 19 (66%) patients in whole blood prior to therapy. In the group

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR9166" target="_blank" >NR9166: Plazmatická EBV-DNA jako biologický marker u pacientů s EBV pozitivním Hodgkinovým lymfomem a její využití v predikci odpovědi na léčbu</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

APMIS

ISSN

0903-4641

e-ISSN

—

Svazek periodika

119

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

10-16

Kód UT WoS článku

000285153600002

EID výsledku v databázi Scopus

—